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Abstract: Uterine leiomyomata present major problem for females. Although they are benign tumors 
their frequency is associated with many symptoms like infertility, abdominal pain, menorrhagia. Authors 
based on their own morphological studies and review of the literature try to indicate main factors causing 
angiogenesis within leiomyomata and its infl uence on tumor growth. Th e strongest proangiogenic factor 
seems to be hypoxia, which stimulates up- and down-regulation of numerous genetically determined 
substances. Also mechanical pressure acting upon newly growing vessels is one of the factors which may 
determine formation of so called “vascular pseudocapsule” around the lesion.
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Introduction
Angiogenesis is currently considered to be a  very important factor controlling growth 
and ability to metastasize of malignant tumors [1]. Role of the angiogenesis in the 
growth of benign tumors still remains unclear. However if we consider the model of de-
velopment of uterine fi broids based on adaptation of the vessels of normal vascular bed 
— their further regression and subsequent vascularization “de novo” — it may appear 
that angiogenesis plays key role also in the development of benign tumors. Formation of 
“vascular pseudocapsule” in the periphery of the fi broid requires undoubtedly involve-
ment of pro-angiogenic factors. Although studies which consider angiogenic activity of 
uterine leiomyomata and surrounding myometrium, bring unanimous results by far. 
It was proved that uterine fi broids are source of the whole palette of growth 
factors, which seem to be probable or to be angiogenic factors, too. Family of factors 
associated with uterine leiomyomata consists of: vascular endothelial growth factor 
(VEGF), platelet-derived growth factor (PDGF), platelet derived endothelial cells 
growth factor (PD-ECGF), epidermal growth factor (EGF), transforming growth 
factor (TGF alpha and beta), basic fibroblast growth factor (bFGF), insulin-like 
growth factor (IGF), adnenulomedullin (ADM) [2–12]. Some of mentioned factors, 
i.e. VEGF-A [6], bFGF [3, 11] and IGF-I [7] show increased expression in the uterine 
leiomyomata, comparing to the surrounding myometrium. Other factors, i.e. EGF 
[6], TGF-beta [13] show decreased expression in fi broids. It is generally assumed that 
VEGF and ADM show increased activity in uterine myomas [2]. From another hand 
however we have to cope with contrary reports. Lee and Novak described increased 
level of TGF-beta mRNA [10], while Vollenhoven et al. [14] did not show signifi cant 
changes in expression of EGF and TGF-beta of fi broids and surrounding myometrium. 
Similar results were achieved by Harrisson-Woolrych et al. in EGF mRNA [9].
Material and methods
Th e study was carried out on 51 human uteri of females aged between 32–66 years, 
which died because of diseases not associated with the internal female genital tracts, 
obtained during autopsies. Th e study was approved by local Ethical Committee. Th e 
whole material was collected upon 12–22 hrs from the moment of decease. Th e pro-
tocol used was described in details in [14, 15]. Additionally 5 specimens were injected 
with water solution of acrylic emulsion (Liquitex R, Binney and Smith, USA) [16]. 
Th us obtained material was cut into slides, which aft er dehydration in rising concen-
trations of ethyl alcohol and immersed in methyl benzoesane were paraffi  nized and 
dyed with hematoxylin and eosin. Th e material was studied under light microscope 
(magnifi cation 5–40x). Some of tissue blocs were deparaffi  nized and hydrated to per-
form immunohistochemical reaction for von Willebrandt factor. 
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Results and discussion
Most of proangiogenic factors are located in cytoplasm of smooth muscle cells — of 
both myometrium and cells of blood vessels. TGF-alpha, EGF and FGF-2 were ob-
served also within endothelial cells, and IGF-1 in the fi broblasts of connective tissue 
[6]. It is interesting that bFGF is located mainly within intercellular matrix, and its 
relatively high level was associated with its condensation [11].
Growth factors present in fi broids may infl uent all its factors: smooth muscle cells, 
vascular endothelial cells and connective tissue fi broblasts. Th eir specifi c participation 
in angiogenesis hasn’t been suffi  ciently elicited yet. It is interesting that so far any 
relationship between increased vascular density and level of VEGF expression 
hasn’t been proved, and VEGF is considered to be the main factor which stimulates 
angiogenesis [17, 18]. Th at kind of positive correlation was observed according to PD-
ECGF, TGF-alpha and ADM. Expression of this last factor correlates positively also 
with the endothelial cells proliferation index [2]. ADM, opposite to VEGF has limited 
mitogenic action, limited almost to endothelial cells only. Furthermore, it shows 
relatively wide infl uence on proliferation and growth of tumor cells, both malignant 
and benign, and may play key role in angiogenesis of uterine leiomyomata. 
Regulation of angiogenic factors probably follows few complicated mechanisms. 
Genetic aberrations of chromosomes 6, 7, 12, and 14 may cause increased tolerance 
considering angiogenic growth factors or decreased ability of production or response 
to angiogenic factors with the growth of the tumor. Genetic failures leading to 
increased sensitivity to angiogenic inhibitors, i.e. angiostatin [19], may be responsible 
for clinical picture of necrosis within certain leiomyomata.
Factors which stimulate angiogenesis, i.e. VEGF and substances from group of 
FGF, prove frequently increased activity in hypoxia, tissue damage and growth of 
new tissues. ADM and VEGF prove certain similarities, because both these strong 
angiogenic factors are induced by hypoxia, and both increase vascular permeability. 
It has been well documented that on induction both these factors require hypoxia 
stadium [2]. It is postulated that similar to most of the neoplasms, uterine leiomyomata 
show decreased level of oxygen.
In our studies one could observe relatively dense network of vessels penetrating 
the lesions, and in the specimens injected with Liquitex R we could see compressed 
blood vessels — even not fi lled with dye which were visible by staining using von 
Willebrandt factor. Th ese compressed by growing tumor masses vessels were useless 
— and such condition led to signifi cant hypoxia, a strong proangiogenic condition.
It is obvious that angiogenesis in the uterine fi broids may be infl uenced by ovarian 
steroids. Estrogens regulate expression of VEGF in the uterus at the transcription 
level [20]. In physiology they promote endometrial angiogenesis through regulation 
of VEGF expression in glandular cells and stroma [21]. Regulation of bFGF and its 
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receptors seems to be also dependent on the level of ovarian hormones [12]. PDGF 
and bFGF levels decrease in patients treated with agonists of gonadotropin releasing 
hormone (GnRH) [22, 23]. From another hand however in these patients nobody 
observed specifi c changes of microvessel density nor VEGF expression in fi broids 
[8, 24]. However the endothelial cells proliferation index of fi broids, myometrium 
and endometrium did not diff er in particular phases of the menstruation cycle [2]. 
Xu et al. postulated that progesterone receptor modulator CDB-2914 down-regulates 
vascular endothelial growth factor, adrenomedullin and their receptors and modulates 
progesterone receptor content in cultured human uterine leiomyoma cells [25]. Also 
Catherino et al [26] indicate new potential targets for genetic researches.
In this context diff erences in vascular density observed between leiomyomata 
and the normal tissue may at least partially be result of diff erent level of estrogen 
receptors (ER), which was shown in fi broids, comparing to the level of ER in regular 
myometrium [25, 27, 28]. Th e level of ER alpha RNA and immunoreactivity ER 
alpha are higher in leiomyomata than in surrounding myometrial tissue. Myometrial 
cells and in vitro cultured fibroid cells show increased expression of ER alpha 
receptors, and do not show changes in expression of ER beta. On the other hand 
endothelium of microvessels shows significant changes in expression of ER beta 
receptors [29]. Estrogens play vital role in survival of endothelial cells [30], so on 
this path they can stimulate changes which support or/and cause angiogenic response 
of microvessel endothelial cells, thus promoting growth of the new vessels within 
a tumor.
Despite expression of numerous proangiogenic factors within uterine leiomyomata, 
angiogenesis seems not to be specially outstanding during tumorigenesis, what is 
confi rmed by relatively low vascular density (Fig. 1).
Th is hypothesis was lastly confi rmed by studies of Weston et al., which proved 
in the leiomyomata decreased expression of two factors promoting angiogenesis: 
connective tissue growth factor (CTGF) and cysteine rich factor inducing angiogenesis 
(CYR61), and also decreased expression of collagen 4 alpha2 (COL4A2), precursor of 
angiogenic inhibitor — canstatine. Th is is why fi broids comparing to the surrounding 
myometrium show antiangiogenic profi le of gene expression.
For contrast, the most intense angiogenesis seems to occur at the border 
leiomyoma/myometrium, which leads to formation of vascular rich “pseudocapsule”, 
visible especially in greater uterine leiomyomata. It might be a  result of release of 
proangiogenic factors through stimulated by fi broid angiogenesis within surrounding 
myometrium. As a matter of fact we do not know, if the arrangement of the vessels 
in the central region of the lesion is resulted by physical pressure of the new vessels 
‘invading’ the tumor or is it result of activity of the factors which inhibit angiogenesis 
in these parts of the tumor? Th is problem remains in the sphere of speculations, 
by far.
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Fig. 1. Uterus of 43 years old female. Subserous leiomyoma injected through the arteries with water solu-
tion of Acrylic emulsion Liquitex R (Binney and Smith) (*). Immunostaining for von Willebrandt fac-
tor. Centrally visible numerous minute, not fi lled with emulsion vessels (arterioles and capillaries) (↑). 
Bar = 500 μm.
Confl ict of interest
None declared.
References
 1. Folkman J.: Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002; 29, Suppl. 16: 
15–18.
 2. Hague S., Zhang L., Oehler M.K., Manek S., MacKenzie I.Z., Bicknell R., Rees M.C.P.: Expression of 
hypoxically regulated angiogenic factor adrenomedullin correlates with uterine leiomyoma vascular 
density. Clin Cancer Res. 2000; 6: 2808–2814.
 3. Anania C.A., Stewart E.A., Quade B.J., Hill J.A., Nowak R.A.: Expression of the fi broblast growth 
factor receptor in women with leiomyomas and abnormal uterine bleeding. Mol Hum Reprod. 1997; 
3: 685–691.
 4. Anderson J.: Factors in fi broid growth. Bailliére’s Clin Obstet Gynecol. 1998; 12: 225–243.
 5. Arici A., Sozen I.: Transforming growth factor-beta3 is expressed at high levels in leiomyoma where 
it stimulates fi bronectin expression and cell proliferation. Fertil Steril. 2000; 73: 1006–1011.
42 Monika Konarska, Anna Natalia Wrona, et al.
 6. Dixon D., He H., Haseman J.K.: Immunohistochemical localization of growth factors and their 
receptors in uterine leiomyomas and matched myometrium. Environ Health Perspect. 2000; 108, 
Suppl. 5: 797–802.
 7. Englund K., Lindblom B., Carlstrom K., Gustavsson I., Sjoblom P., Blanck A.: Gene expression and 
tissue concentrations of IGF-I in human myometrium and fibroids under different hormonal 
conditions. Mol Hum Reprod. 2000; 6: 915–920.
 8. Gentry C.C., Okolo S.O., Fong L.W.F.T., Crow J.C., Maclean A.B., Perrett C.W.: Quantifi cation of 
vascular endothelial growth factor—A in leiomyomas and adjacent myometrium. Clin Sci. 2001; 
101: 691–695.
 9. Harrison-Woolrych M.L., Charnock-Jones D.S., Smith S.K.: Quantifi cation of messenger ribonucleic 
acid for epidermal growth factor in human myometrium and leiomyomata. J Clin Endocrinol 
Metab. 1995; 80: 1853–1858.
10. Lee B.S., Nowak R.A.: Human leiomyoma smooth muscle cells show increased expression of 
transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative eff ects 
of TGF beta. J Clin Endocrinol Metab. 2001; 86: 913–920.
11. Mangrulkar R.S., Ono M., Ishikawa M., Takashima S., Klagsbrun M., Nowak R.A.: Isolation and 
characterization of heparin-binding growth factors in human leiomyomas and normal myometrium. 
Biol Reprod. 1995; 53: 636–646.
12. Wu X., Blanck A., Olovsson M., Moller B., Lindblom B.: Expression of basic fi broblast growth factor 
(bFGF), FGF receptor 1 and FGF receptor 2 in uterine leiomyomas and myometrium during the 
menstrual cycle, aft er menopause and GnRHa treatment. Acta Obstet Gynecol Scand. 2001, 80: 497–504.
13. Hong T., Shimada Y., Uchida S., Itami A., Li Z., Ding Y., Kaganoi J., Komoto I., Sakurai T., 
Imamura  M.: Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and 
leiomyoma. Int J Mol Med. 2001; 8: 141–148.
14. Vollenhoven B.J., Pearce P., Herington A.C., Healy D.L.: Messenger ribonuclein acid expression of the 
insulin-like growth factors and their binding proteins in uterine fi broids and myometrium. J Clin 
Endocrinol Metab. 1995; 76: 1106–1110.
15. Walocha J.A., Miodoński A.J., Szczepański W., Skrzat J., Stachura J.: Two types of vascularisation of 
intramural uterine leiomyomata revealed by corrosion casting and immunohistochemical study. 
Folia Morphol. (Warsz.) 2004; 63, 1: 37–41.
16. Walocha J.A., Miodoński A.J., Nowogrodzka-Zagórska M., Kuciel R., Gorczyca J.: Application of 
a  mixture of glycol polyethylenes for the preparation of microcorrosion casts — an observation. 
Folia Morphol. (Warsz.) 2002; 61, 4: 313–316.
17. Walocha J.A., Szczepański W., Miodoński A.J., Gorczyca J., Skrzat J., Bereza T., Ceranowicz P., 
Lorkowski J., Stachura J.: Application of acrylic emulsion Liquitex R (Binney and Smith) for the 
preparation of injection specimens and immunohistochemical studies—an observation. Folia 
Morphol. 2003; 62 (2), 157–161.
18. Poncelet C., Fauvet R., Feldmann G., Walker F., Madelenat P., Darai E.: Prognostic value of von 
Willebrand factor, CD34, CD31, and vascular endothelial growth factor expression in women with 
uterine leiomyosarcomas. J Surg Oncol. 2004; 86: 84–90.
19. O’Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead R., Olsen B.R., 
Folkman J.: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases 
by a Lewis Lung Carcinoma. Cell. 1994; 79: 315–328.
20. Hyder S.M., Huang J.C., Nawaz Z., Boettger-Tong H., Makela S., Chiapetta C., Stancel G.M.: 
Regulation of Vascular Endothelial Growth Factor Expression by Estrogens and Progestins. 
Environm. Health Perspect. 2000, 108: 785–790.
21. Albrecht E.D., Babischkin J.S., Lidor Y., Anderson L.D., Udoff  L.C., Pepe G.J.: Eff ect of estrogen on 
angiogenesis in co-cultures of human endometrial cells and microvascular endothelial cells. Hum 
Reprod. 2003; 18, 10: 2039–2047.
 Angiogenesis and pro-angiogenic factors in uterine fi broids  — facts and myths 43
22. Di Lieto A., De Rosa G., De Falco M., Ianotti F., Staibano S., Pollio F., Scaramellino M., Salvatore G.: 
Relationship between platelet-derived growth factor expression in leiomyomas and uterine volume 
changes aft er gonadotropin-releasing hormone agonist treatment. Hum Pathol. 2002; 33: 220–224.
23. Di Lieto A., De Falco M., Staibano S., Ianotti F., Scaramellino M., Mansueto G., Granata P., 
Pontillo  M., Pollio F., De Rosa G.: Eff ects of gonadotropin-releasing hormone agonists on uteri 
volume and vasculature and on the immunohistochemical expression of basic fi broblast growth 
factor (bFGF) in uterine leiomyomas. Int J Gynecol Pathol. 2003; 22: 353–358.
24. Abulafi a O., Kleinhaus K., Levi G., Lee Y.C., Sherer D.M.: Eff ect of gonadotropin-releasing hormone 
agonist treatment upon angiogenesis in uterine leiomyoma. Gynecol Obstet Invest. 2001; 52: 
108–113.
25. Xu Q., Ohara N., Chen W., Liu J., Sasaki H., Morikawa A., Sitruk-Ware R., Johansson E.D.B., 
Maruo T.: Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth 
factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured 
human uterine leiomyoma cells. Hum Rep. 2006; 21 (9): 2408–2416. doi: 10.1093/humrep.del159.
26. Catherino W., Salama A., Potlog-Nahari C., Leppert P., Tsibris J., Segars J.: Gene expression studies in 
leiomyomata: New directions for research. Semin Rep Med. 2004; 22 (2): 83–90.
27. Benassayag C., Leroy M.J., Rigourd V., Robert B., Honore J.C., Mignot T.M., Vacher-Lavenu M.C., 
Chapron C., Ferre F.: Estrogen receptors (ERα/ERβ) in normal and pathological growth of the 
human myometrium: pregnancy and leiomyoma. Am J Physiol. 1999; 39: E1112–1118.
28. Wang H., Wu X., Englund K., Masironi B., Eriksson H., Sahlin L.: Diff erent expression of estrogen 
receptors alpha and beta in human myometrium and leiomyoma during the proliferative phase of 
the menstrual cycle and aft er GnRHa treatment. Gynecol Endocrinol. 2001; 15: 443–452.
29. Gargett C.E., Bucak K., Zaitseva M., Chu S., Taylor N., Fuller P.J., Rogers P.A.W.: Estrogen receptors-α 
and -β expression in microvascular endothelial cells and smooth muscle cells of myometrium and 
leiomyoma. Mol Hum Reprod. 2002; 8, 8: 770–775.
30. Razandi M., Pedram A., Levin E.R.: Estrogen signals to the preservation of endothelial cell form and 
function. J Biol Chem. 2000; 275: 38540–38546.
31. Weston G., Trajstman A.C., Gargett C.E., Manuelpillai U., Vollenhoven B.J., Rogers P.A.W.: Fibroids 
display an anti-angiogenic gene expression profi le compared with adjacent myometrium. Mol Hum 
Reprod. 2003; 9: 541–549.
